Werewolf Therapeutics (HOWL) shares more than doubled on Friday morning as investors reacted to the company’s definitive agreement to merge with privately held Ambros Therapeutics.
Once the transaction is completed, HOWL shareholders will retain about 6.8% ownership of the joint company, its management revealed in a press release on Aug. 21.
Despite the explosive surge, Werewolf Therapeutics stock remains down more than 10% versus its year-to-date high.
What’s Behind Werewolf Therapeutics Stock’s Rally
Investors cheered the announcement mostly because Werewolf is gaining access to Ambros’s late-stage neridronate program, which is being developed as a treatment for Complex Regional Pain Syndrome Type 1 (CRPS-1).
Ambros began its pivotal CRPS-RISE Phase 3 clinical trial in June, and neridronate has previously received FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations.
Moreover, the deal brings substantial funding as well. Investors have committed $150 million through an oversubscribed PIPE, with the combined entity expected to be funded through the CRPS-RISE Phase 3 results and planned New Drug Application (NDA) submission.
Could HOWL Shares Rip Higher From Here?
Potentially, yes — but Friday’s move has already baked in the merger optimism rather meaningfully.
There is still a major catalyst pipeline ahead; the combined company will focus on neridronate, with CRPS-RISE Phase 3 results expected in 2028.
If the trial succeeds, the asset could potentially become the first FDA-approved therapy for CRPS-1, a market with an estimated 65,000 newly diagnosed patients in the U.S. annually and no currently approved treatment.
However, investors should not overlook the substantial dilution embedded in the transaction. Existing Werewolf shareholders are expected to own only about 6.8% of the combined company, while Ambros holders receive 71.7% and PIPE investors 21.5%.
In short, further upside is possible, but the next leg higher will depend on neridronate’s progress rather than the merger announcement itself.
Wall Street’s View on Werewolf Therapeutics
Heading into Aug. 21, Wall Street had a consensus “Moderate Buy” rating on HOWL shares, with a mean price target of about $6.
This means that experts viewed Werewolf Therapeutics at less than a dollar per share as notably undervalued, even as a standalone company.
On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
/A%20close-up%20of%20an%20AMD%20office%20by%20gehapromo%20via%20Adobe%20Stock.jpeg)
/Applied%20Materials%20Inc_%20campus%20sign-by%20Sundry%20Photography%20via%20iStock.jpg)
